Product Description: Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 research. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Jie Wang, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717.
CAS Number: 1858168-59-8
Molecular Weight: N/A
Compound Purity: 98.10
Research Area: Cancer; Inflammation/Immunology
Solubility: H2O
Target: PD-1/PD-L1